Pharming Group Receives Accelerated Assessment in Europe for leniolisib for the Treatment of Rare Immunodeficiency, APDS ...Middle East

EMA accelerated assessment allows a shorter review period for leniolisib from a standard 210 days to 150 days Pharming is on track to submit its Marketing Authorisation Application for leniolisib in H2 2022 LEIDEN, the Netherlands, Aug. 1, 2022 /PRNewswire/ -- Pharming Group N.V....

Read More Details
Finally We wish PressBee provided you with enough information of ( Pharming Group Receives Accelerated Assessment in Europe for leniolisib for the Treatment of Rare Immunodeficiency, APDS )

Also on site :

• Trader Joe's is Giving This Viral Chocolate Bar Its Own Spin and Shoppers 'Can't Wait' To Try It
• Sputnik V creator warns of global ‘cat flu’ pandemic
• Former Microsoft engineer fired over protest on Israel AI ties